Drugs / KA2507
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03008018 | Aug 2017 → Jun 2020 | cancer | Karus Therapeutics Limited | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04186156 | Mar 2020 → Mar 2023 | biliary tract cancer | Karus Therapeutics Limited | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KA2507 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03008018 ↗ |
| Action | Inhibit | “potent and selective inhibitor of the HDAC6 enzyme” NCT03008018 ↗ |
| Modality | Small molecule | “KA2507, an orally-active new chemical entity” NCT03008018 ↗ |
| Route | Oral | “KA2507 was administered orally using a 3+3 dose-escalation design (NCT03008018).” PMID 33947698 ↗ May 2021 |
| Target | HDAC6 | “potent and selective inhibitor of the HDAC6 enzyme” NCT03008018 ↗ |